SCHEMBL1437236

SCHEMBL1437236

Cc1cccc(C(=N)Nc2cc(Cl)ccc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.45
MEN1 O00255 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
KDM4E B2RXH2 3/20 0.45
LMNA P02545 3/20 0.45
HTT P42858 2/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KCNK3 O14649 4/20 0.45
KCNK9 Q9NPC2 3/20 0.45
GAA P10253 3/20 0.40
ALDH1A1 P00352 2/20 0.39
TP53 P04637 1/20 0.39
CNR2 P34972 1/20 0.38
KCNH2 Q12809 1/20 0.38
MCL1 Q07820 1/20 0.38
KCNMA1 Q12791 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893687 0.87 GAA (0.47) KMT2AMEN1SMN1; SMN2KDM4ELMNA
SCHEMBL20052984 0.74 KMT2A (0.54) KMT2AMEN1SMN1; SMN2HTTHPGD
SCHEMBL1437599 0.73 GAA (0.50) KMT2AMEN1SMN1; SMN2KDM4ELMNA
SCHEMBL20053034 0.70 MEN1 (0.57) KMT2AMEN1SMN1; SMN2MAPTNPSR1
SCHEMBL1436924 0.70 GAA (0.50) SMN1; SMN2KDM4ELMNAHTTMAPT
SCHEMBL1437427 0.70 GAA (0.50) KMT2AMEN1SMN1; SMN2KDM4ELMNA
SCHEMBL28810353 0.70 NOX1 (0.53) KMT2ASMN1; SMN2LMNAHTTMAPT
SCHEMBL8268335 0.69 HDAC8 (0.50) KMT2AMEN1SMN1; SMN2HPGDKCNK3
SCHEMBL29967222 0.69 HDAC8 (0.60) KMT2AMEN1SMN1; SMN2HPGDKCNK3
SCHEMBL396668 0.69 HDAC8 (0.60) KMT2AMEN1SMN1; SMN2HPGDKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 KMT2A 1512/4885MEN1 510/4885SMN1; SMN2 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.